Wide Ranks

ATRA

Atara Biotherapeutics, Inc.

12.18

Top Statistics
Market Cap 70 M Forward PE -1.33 Revenue Growth 2892.70 %
Current Ratio 0.42 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -290.20 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.5400 Enterprise / Revenue 1.40 Price To Sales Trailing12 Months 1.12
Profitability
Profit Margins -290.20 % Operating Margins -62.41 %
Balance Sheet
Total Cash 35 M Total Cash Per Share 7.18 Total Debt 52 M
Total Debt To Equity Current Ratio 0.42 Book Value Per Share -23.30
All Measures
Short Ratio 711.00 % Message Board Id finmb_248196818 Shares Short Prior Month 526379
City Thousand Oaks Uuid 2e7d1e9f-6492-3d1e-8dac-1008d2ea8165 Previous Close 12.26
First Trade Date Epoch Utc 1 B Book Value -23.30 Beta 0.4950
Total Debt 52 M Volume 36313 Last Split Date 1 B
Fifty Two Week Low 6.50 Total Cash Per Share 7.18 Total Revenue 62 M
Shares Short Previous Month Date 1 B Target Median Price 14.00 Audit Risk 3
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -62.41 %
Target Mean Price 14.75 Net Income To Common -181048000 Short Percent Of Float 0.1136
Implied Shares Outstanding 5 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 100780 Average Volume10days 100780 Total Cash 35 M
Next Fiscal Year End 1 B Revenue Per Share 12.26 Held Percent Insiders 0.2215
Ebitda Margins -259.87 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 12.26
Target Low Price 10.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 9.46
Open 12.25 Free Cashflow -2966750 State CA
Dividend Yield 0.00 % Return On Assets -0.5748 Time Zone Short Name EST
Board Risk 7 Trailing Eps -25.32 Day Low 11.96
Address1 2380 Conejo Spectrum Street Shares Outstanding 5 M Compensation Risk 9
Price Hint 2 Target High Price 21.00 Website https://www.atarabio.com
52 Week Change -0.2618 Average Volume 149171 Forward Eps -8.77
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 25.40 %
Last Split Factor 1:25 Regular Market Day High 12.59 Is_sp_500 False
Profit Margins -290.20 % Fifty Two Week High 39.50 Day High 12.59
Shares Short 636280 Regular Market Open 12.25 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 1.40 Revenue Growth 2892.70 %
Shares Percent Shares Out 0.1121 Operating Cashflow -142008992 Currency USD
Time Zone Full Name America/New_York Market Cap 70 M Is_nasdaq_100 False
Zip 91320 Quote Type EQUITY Industry Biotechnology
Long Name Atara Biotherapeutics, Inc. Overall Risk 8 Regular Market Day Low 11.96
Held Percent Institutions 0.5082 Current Price 12.18 Address2 Suite 200
Enterprise To Ebitda -0.5400 Financial Currency USD Current Ratio 0.42
Gross Margins -201.90 % Industry Disp Biotechnology Number Of Analyst Opinions 4
Country United States Float Shares 4 M Two Hundred Day Average 12.32
Governance Epoch Date 1 B Enterprise Value 87 M Price To Sales Trailing12 Months 1.12
Forward PE -1.33 Regular Market Volume 36313 Ebitda -162124992
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom.

Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.

Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis.

The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.

Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.